ArrowMark Colorado Holdings’s MaxCyte MXCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-83,659
Closed -$132K 319
2025
Q3
$132K Hold
83,659
﹤0.01% 301
2025
Q2
$182K Sell
83,659
-1,235,236
-94% -$2.99M ﹤0.01% 299
2025
Q1
$3.6M Sell
1,318,895
-38,808
-3% -$153K 0.06% 201
2024
Q4
$5.65M Sell
1,357,703
-37,244
-3% -$141K 0.08% 185
2024
Q3
$5.43M Buy
1,394,947
+169,250
+14% +$713K 0.07% 185
2024
Q2
$4.8M Sell
1,225,697
-32,503
-3% -$140K 0.06% 205
2024
Q1
$5.27M Sell
1,258,200
-115,577
-8% -$543K 0.06% 211
2023
Q4
$6.46M Sell
1,373,777
-1,035,261
-43% -$4.03M 0.07% 187
2023
Q3
$7.52M Sell
2,409,038
-167,222
-6% -$672K 0.09% 160
2023
Q2
$11.8M Buy
2,576,260
+277,186
+12% +$1.27M 0.13% 137
2023
Q1
$11.4M Buy
2,299,074
+40,842
+2% +$201K 0.13% 128
2022
Q4
$12.3M Buy
2,258,232
+30,133
+1% +$185K 0.15% 120
2022
Q3
$14.5M Buy
2,228,099
+73,862
+3% +$412K 0.18% 115
2022
Q2
$10.2M Buy
2,154,237
+861,524
+67% +$4.24M 0.12% 157
2022
Q1
$9.04M Buy
1,292,713
+70,963
+6% +$484K 0.08% 200
2021
Q4
$12.4M Buy
1,221,750
+43,826
+4% +$471K 0.1% 173
2021
Q3
$14.4M Buy
+1,177,924
New +$17.8M 0.11% 153

Other funds holding MXCT

ArrowMark Colorado Holdings's MXCT Position: Q4 2025 in Review

ArrowMark Colorado Holdings sold out of MaxCyte (MXCT) in Q4 2025, closing a stake of 83,659 shares — an estimated $132K sold.

ArrowMark Colorado Holdings first reported a position in MXCT in Q3 2021 and held it in 17 quarters. The position peaked at $14.5M in Q3 2022. 112 funds tracked by Wall St. Rank hold MXCT as of Q4 2025.

  • ArrowMark Colorado Holdings reported no remaining MaxCyte position as of Q4 2025 after selling out during the quarter.
  • ArrowMark Colorado Holdings sold 83,659 MaxCyte shares in Q4 2025, an estimated $132K.
  • ArrowMark Colorado Holdings first reported a position in MaxCyte in Q3 2021 and held it in 17 quarters.
  • ArrowMark Colorado Holdings's MaxCyte position peaked at $14.5M in Q3 2022.
  • 112 funds tracked by Wall St. Rank held MaxCyte as of Q4 2025.

Based on ArrowMark Colorado Holdings's 13F filing for Q4 2025, filed 17 Feb 2026.